ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

In Brief: Transition Team Denies It Is Seeking New NCI Director; Garb Undergoes Surgery At M.D.A

November 28, 1980

Hiring Freeze Squeezes NIH, NCI

August 3, 1979

HHS Proposes Stronger Health Warnings On Cigarette Packages, Ads

November 12, 2010

In Brief: Greenwald Reportedly Considered For CDC Job, Harold Amos On NIH Search Committee

July 14, 1989

In Brief: 163 PIs Hold Both Contracts, Grants; Hopkins Scientists Questions Retrospective Diet Studies

August 27, 1976

Obituary: Lawrence Garfinkel, ACS Epidemiologist

January 22, 2010